HLB Co., Ltd. (KOSDAQ:028300)
South Korea · Delayed Price · Currency is KRW 45,800
+4,600 (11.17%)
Oct 21, 2025, 3:30 PM KST
HLB Co., Ltd. Revenue
HLB Co., Ltd. had revenue of 15.73B KRW in the quarter ending June 30, 2025, with 6.34% growth. This brings the company's revenue in the last twelve months to 75.57B, up 69.07% year-over-year. In the year 2024, HLB Co., Ltd. had annual revenue of 68.13B with 58.80% growth.
Revenue (ttm)
75.57B
Revenue Growth
+69.07%
P/S Ratio
71.52
Revenue / Employee
481.36M
Employees
157
Market Cap
5.41T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 68.13B | 25.23B | 58.80% |
| Dec 31, 2023 | 42.90B | -136.81B | -76.13% |
| Dec 31, 2022 | 179.71B | 109.88B | 157.37% |
| Dec 31, 2021 | 69.83B | 13.65B | 24.30% |
| Dec 31, 2020 | 56.18B | 17.76B | 46.22% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.03T |
| Celltrion | 3.75T |
| Yuhan | 2.17T |
| Hanmi Pharm. | 1.47T |
| SK Biopharmaceuticals | 620.28B |
| PharmaResearch | 449.81B |
| Sam Chun Dang Pharm. | 215.10B |
| ALTEOGEN | 158.06B |